EUCTR2019-001598-10-GR
Active, not recruiting
Phase 1
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous Injections of a Sustained-Release VIP Analogue, PB1046, in Adult Subjects with Symptomatic Pulmonary Arterial Hypertension
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Symptomatic Pulmonary Arterial Hypertension
- Sponsor
- PhaseBio Pharmaceuticals, Inc.
- Enrollment
- 63
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects will be eligible for inclusion in the study if they meet all the following criteria at screening and up to the time of first dose as indicated:
- •1\. Male and female subjects with PAH, \=18 and \= 79 years of age, who are symptomatic and have reduced exercise capacity due primarily to their PAH diagnosis and have been assessed by a qualified individual (i.e. physician, physician assistant, nurse practitioner) to be in NYHA/WHO functional class II or III
- •2\. Willing and able to sign a written informed consent prior to all study\-related procedures
- •3\. Subjects with PAH belonging to one of the following subgroups of the NICE Clinical Classification of Pulmonary Hypertension Group 1:
- •a. Idiopathic
- •b. Heritable
- •c. Drug or toxin\-induced
- •d. Associated with connective tissue disease, HIV infection, portal hypertension, congenital heart disease (pulmonary\-to\-systemic shunt, e.g., atrial septal defect (ASD) or patent ductus arteriosus (PDA), at least 1 year after surgical repair)
- •4\. Two 6MWT results \> 50 m and \< 550 m prior to randomization with results \+/\- 10% of each other. Note: Up to four tests may be conducted between Screening and Randomization for eligibility purposes (no more than two 6MWT may be performed on the same day, and must be completed at least two hours apart)
- •5\. Hemodynamic assessment of PAH by right heart catheterization (RHC) demonstrating elevated mPAP and PVR as indicated below during the Screening Period
Exclusion Criteria
- •Subjects will be excluded from the study if they meet any of the following criteria:
- •1\. Concomitant medical disorder, condition, or history, that in the opinion of the Investigator would impair the subject’s ability to participate in or complete the requirements of the study
- •2\. Concomitant medical disorder that is expected to limit the subject’s life\-expectancy to \= 1 year
- •3\. Pregnant or lactating female subjects
- •4\. First positive result from serology testing at Visit 1 (screening labs) for HIV, HBsAg, or HCV prior to randomization
- •5\. Participation in another investigational drug study within 30 days prior to screening or participating in a non\-medication study which, in the opinion of the Investigator, would interfere with the study compliance or outcome assessments
- •6\. Use of subcutaneous prostanoid/prostacyclin therapy for PAH within 30 days prior to the screening visit
- •7\. More than mild mitral or aortic valve disease, left ventricular ejection fraction \< 50%, or left ventricular regional wall motion abnormality suggestive of active coronary artery disease on documented 2D\-echocardiography occurring within 12 months of Screening
- •8\. Sustained SBP \< 95 mmHg and/or diastolic blood pressure (DBP) \< 50 mmHg (confirmed by a duplicate seated reading) on at least 3 consecutive readings (self\-monitored or office) at screening and prior to dosing, or overt symptomatic hypotension
- •9\. Sustained resting heart rate \>110 beats per minute (BPM) (confirmed by duplicate assessments of office vital signs or consecutive ECG assessments) on at least 3 consecutive readings at screening and prior to dosing
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly Subcutaneous Injections of PB1046 (study drug) in Subjects With Symptomatic Pulmonary Arterial HypertensioSymptomatic Pulmonary Arterial HypertensionMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2019-001598-10-ESPhaseBio Pharmaceuticals, Inc.63
Active, not recruiting
Phase 1
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly Subcutaneous Injections of PB1046 (study drug) in Subjects With Symptomatic Pulmonary Arterial HypertensioEUCTR2019-001598-10-BGPhaseBio Pharmaceuticals, Inc.63
Active, not recruiting
Phase 1
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly Subcutaneous Injections of PB1046 (study drug) in Subjects With Symptomatic Pulmonary Arterial HypertensioSymptomatic Pulmonary Arterial HypertensionMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2019-001598-10-PLPhaseBio Pharmaceuticals, Inc.63
Active, not recruiting
Phase 1
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly Subcutaneous Injections of PB1046 (study drug) in Subjects With Symptomatic Pulmonary Arterial HypertensioEUCTR2019-001598-10-ATPhaseBio Pharmaceuticals, Inc.63
Active, not recruiting
Phase 1
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly Subcutaneous Injections of PB1046 (study drug) in Subjects With Symptomatic Pulmonary Arterial HypertensioEUCTR2019-001598-10-HUPhaseBio Pharmaceuticals, Inc.63